Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 99 Show results per page	View Search Criteria \| Help With Results


1.		Stem Cell Transplant for Bone Marrow Failures

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Supportive care, Treatment				Active				35 and under				Other				9504M09637 MT2000-18, NCT00176878


2.		In-Vivo Activated T-Cell Depletion to Prevent GVHD

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Supportive care, Treatment				Active				18 to 75				Other				0705-20 IUCRO-0196 NCT00594308

Last Modified: 9/19/2008 First Published: 11/1/2002


3.		Phase III Randomized Study of Daunorubicin and Cytarabine With or Without Gemtuzumab Ozogamicin Followed By Autologous Hematopoietic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia (Autologous Transplantation Arm II Closed to Accrual as of 10/4/2007)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				16 to 60				NCI				ECOG-1900 E1900, NCT00049517

Last Modified: 5/7/2008 First Published: 12/23/2003


4.		Phase III Randomized Study of Nonmyeloablative Conditioning Comprising Low-Dose Total Body Irradiation With Versus Without Fludarabine Followed By HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies at Low or Moderate Risk For Graft Rejection

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Under 75				NCI				FHCRC-1813.00 NCT00075478


5.		TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Active				18 to 80				Other				2003.333 NCT00133887


6.		To Determine the Role of Adding Campath-1H or ATG Given in-Vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				230704-HMO-CTIL NCT00226512

Last Modified: 12/11/2006 First Published: 5/23/2006


7.		Phase III Study of Induction and Maintenance Therapy Comprising Etoposide, Dexamethasone, and Cyclosporine Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Primary Inherited or Severe and Persistent Secondary Hemophagocytic Lymphohistiocytosis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Treatment				Active				Under 18				Other				CCLG-LCH-2006-02 EU-20619, UKCCSG-HLH-2004, EUDRACT-2005-002187-28, NCT00334672

Last Modified: 9/19/2008 First Published: 8/24/2006


8.		Phase III Randomized Study of Conventional Combination Chemotherapy With Versus Without Gemtuzumab Ozogamicin in Young Patients With Newly Diagnosed Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Under 30				NCI				COG-AAML0531 AAML0531, NCT00372593

Last Modified: 12/4/2007 First Published: 10/14/2006


9.		Phase III Randomized Study of Irinotecan Hydrochloride With Versus Without Panitumumab or Cyclosporine in Patients With Fluorouracil-Resistant Advanced or Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other, Pharmaceutical / Industry				CTRU-PICCOLO-MO-05-7289 EUDRACT-2005-003492-20, CTAAC-CTRU-PICCOLO-MO-05-7289, AMGEN-CTRU-PICCOLO-MO-05-7289, EU-20647, NCT00389870

Last Modified: 8/6/2008 First Published: 2/16/2007


10.		Phase III Randomized Study of Filgrastim (G-CSF)-Mobilized Matched-Sibling Donor Peripheral Blood Stem Cell Transplantation Versus G-CSF-Stimulated Matched-Sibling Donor Bone Marrow Transplantation in Patients With Hematologic Malignancies or Other Diseases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				16 to 65				NCI				CBMTG-0601 NCT00438958

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute